CIVIL-SOCIETY-20
22.3.2020 18:51:13 CET | Business Wire | Press release
The following is a statement by Civil 20:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005022/en/
The events of this year alone, starting with the bushfires in Australia and moving to the outbreak of COVID-19, underscored the ever-growing complexity of our global shared challenges and expose the weaknesses of the current dominant economic system, and how it deepens inequalities between individuals and countries. We ask that G20 leaders recognize our new global reality and reorient this year’s G20 priorities towards building a more resilient global governance.
G20 leaders need to uphold the principles of human rights, civic engagement, and democracy. As the crisis develops, the C20 observes with great alarm the continued deterioration of the situation for many vulnerable groups in different societies. Governments must protect and extend medical care to all people without leaving anyone behind.
The infodemic surrounding the disease is equally fatal to the virus. The C20 stands in solidarity with communities suffering as a result of different governments’ lack of transparency. Governments are accountable in their response to the crisis, and work on empowering local communities and civil society actors in responding to the outbreak.
We can learn from previous public health emergencies the importance of quality care continuum, protection of human rights, anti-discrimination and isolation of people living with the diseases and affected communities. COVID-19 is a sobering reminder that we need to increase investment in what we know works: strong international partnerships, building health care delivery systems that reach everyone, research and development, and an approach to care that prioritizes the most marginalized. The C20 urges that G20 leaders consider the recommendations in the statement on pandemic preparedness released jointly with the Business 20, Labor 20, Think 20, Women 20 and Youth 20.
Another emerging lesson out of this emergency, is that hyper-globalization of our supply chains is making our trade systems extremely vulnerable to shocks. The C20 cautions G20 leaders against the ongoing attempts in trade agreement negotiations to open “health markets” to foreign investors and competition, turning health systems into yet another investment opportunity. We worry that the divide between those who can afford healthcare and those who cannot will be exacerbated.
The C20 warns that inequalities will ensue as a consequence of the outbreak. Labor policies need to be put in place to address the needs of the most vulnerable, who cannot afford to sit at home, and prepare for the expected rise in working poverty, especially in countries with a high informal economy, where women are over-represented.
The world is in need of multilateral coordination of an effective response to the economic crisis that provides adequate fiscal and monetary stimulus, while safeguarding liquidity from misuse by speculative activities. A fairly designed stimulus package should take into account not only the interest of businesses and SMEs, but also households, workers, and the most vulnerable.
A problem with multiple dimensions requires a solution by multiple actors. Members of Civil Society and humanitarian NGOs continue to face tightened financial restrictions due to risk and cost aversion by banks in complying with FATF regulations. Such financial exclusion limits our ability to respond to global emergencies.
We implore the G20 Leaders to take immediate action in responding to the substantial impact on education and the dwindling prospects of ensuring access. The world is entirely unequipped to maintain a promise of “education for all”; particularly in contexts where classrooms can no longer provide a safe environment for learning.
The C20 calls on G20 leaders to expand this year’s G20 priorities to vigilantly respond to the changes in the labor market through expanding social protection systems, ensure digital and eLearning is accessible across, prioritize child online safety, address rising risks to debt sustainability in emerging markets as they face urgent financing needs to improve health systems capacity to respond to the COVID-19 outbreak, including debt relief and attending to their exposure to volatile capital flows.
Civil Society 20 (C20) is one of the eight official Engagement Groups of the G20. It provides a platform of Civil Society Organizations around the world to bring forth a non-government and non-business voice.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200322005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
